Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2005-005661-11Phase 2Active
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Pathological complete response. Started Sep 2007; status: active.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2005-005661-11.